|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Nuclear and cytoplasmic interaction of pRb2/p130 and ER-beta in MCF-7 breast cancer cells.
|
16760287 |
2006 |
|
Mammary Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells.
|
19434490 |
2010 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.
|
15355905 |
2004 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
|
18669459 |
2008 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease.
|
16808847 |
2006 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy.
|
15723135 |
2004 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This review addresses the signaling of ERβ and GPER in ERα-negative breast tumors.
|
30687231 |
2018 |
|
Mammary Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
In general, ERβ promoter methylation was found in 44.9% (80/178) of breast tumor samples, significantly higher than the benign breast hyperplasia (44.9% vs. 14.3%, X(2) = 4.986, P = 0.026).
|
22105146 |
2012 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Thus, expression of ERbeta mRNA in breast tumors was found to be inversely associated with the degree of methylation of promoter 0N.
|
14576822 |
2003 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.
|
18698041 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Thus, expression of ERbeta mRNA in breast tumors was found to be inversely associated with the degree of methylation of promoter 0N.
|
14576822 |
2003 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer.
|
17428314 |
2007 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The establishment of a clear association is required; therefore, the current study analyzed the expression patterns of ERα and ERβ in 32 breast tumor tissues using reverse transcription-quantitative polymerase chain reaction.
|
28808484 |
2017 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
|
18216219 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells.
|
19434490 |
2010 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Estrogen receptor-beta: why may it influence clinical outcome in estrogen receptor-alpha positive breast cancer?
|
17617929 |
2007 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
The effect of chemotherapy on status of estrogen receptors in primary tumors and lymph node metastases of human ductal breast cancer.
|
17203178 |
2007 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women.
|
14633679 |
2003 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer--a retrospective study.
|
17640362 |
2007 |
|
Mammary Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
CpG methylation of the ERalpha and ERbeta genes in breast cancer.
|
15254780 |
2004 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
ERbeta exerts multiple stimulative effects on human breast carcinoma cells.
|
15208676 |
2004 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Apigenin suppresses cancer cell growth through ERbeta.
|
17132221 |
2006 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The normal and malignant mammary gland: a fresh look with ER beta onboard.
|
14973391 |
2000 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
|
14715875 |
2004 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
By Western blot analysis, we show that ER-beta protein is expressed in all cancer cell lines tested and in three of five breast tumor samples.
|
10554010 |
1999 |